Cancer molecular Dx firm seeks to obtain $6.6 million

12/24/2012 | GenomeWeb Daily News (free registration)

Epigenomics hopes to obtain $6.6 million in a funding round it plans to launch next month. The company is the maker of the Epi proColon test, a blood-based assay for screening colorectal cancer. Proceeds from the planned fundraising will be used to finance the company's operations as well as expand its capabilities for product distribution.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC